Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Vonapanitase

Generic Name: Vonapanitase

Drug Type: Biotech

CAS Number: 944132-02-9

Unique Ingredient Identifier: 3LWJ2H14I9

Overview

Vonapanitase is under investigation for the treatment of Chronic Kidney Disease.

Background

Vonapanitase is under investigation for the treatment of Chronic Kidney Disease.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Phase 1

Completed

Posted: 2016/11/06

Sponsor:

Proteon Therapeutics

ID:NCT02956993

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Phase 1

Withdrawn

Posted: 2016/11/02

Sponsor:

Proteon Therapeutics

ID:NCT02953496

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Phase 3

Completed

Posted: 2015/04/13

Sponsor:

Proteon Therapeutics

ID:NCT02414841

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

Phase 3

Completed

Posted: 2014/04/10

Sponsor:

Proteon Therapeutics

ID:NCT02110901

Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

Phase 1

Completed

Posted: 2012/06/11

Sponsor:

Proteon Therapeutics

ID:NCT01616290

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy